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Abstract
Lymphostatin (LifA) is a 366 kDa protein expressed by attaching & effacing Escherichia coli. It plays an
important role in intestinal colonisation and inhibits the mitogen- and antigen-stimulated proliferation of
lymphocytes and the synthesis of proinflammatory cytokines. LifA exhibits N-terminal homology with
the glycosyltransferase domain of large clostridial toxins (LCTs). A DTD motif within this region is required
for lymphostatin activity and binding of the sugar donor uridine diphosphate N-acetylglucosamine. As with
LCTs, LifA also contains a cysteine protease motif (C1480, H1581, D1596) that is widely conserved within
the YopT-like superfamily of cysteine proteases. By analogy with LCTs, we hypothesised that the CHD
motif may be required for intracellular processing of the protein to release the catalytic N-terminal domain
after uptake and low pH-stimulated membrane insertion of LifA within endosomes. Here, we created and
validated a C1480A substitution mutant in LifA from enteropathogenic E. coli strain E2348/69. The purified
protein was structurally near-identical to the wild-type protein. In bovine T lymphocytes treated with wild-
type LifA, a putative cleavage product of approximately 140 kDa was detected. Appearance of the putative
cleavage product was inhibited in a concentration-dependent manner by bafilomycin A1 and chloroquine,
which inhibit endosome acidification. The cleavage product was not observed in cells treated with the
C1480A mutant of LifA. Lymphocyte inhibitory activity of the purified C1480A protein was significantly
impaired. The data indicate that an intact cysteine protease motif is required for cleavage of lymphostatin
and its activity against T cells.
 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecom-
mons.org/licenses/by/4.0/).Introduction
Gastrointestinal bacterial infections have a
substantial impact on both human and animal
health. Two prominent pathogens are
enteropathogenic Escherichia coli (EPEC) and
enterohaemorrhagic E. coli (EHEC), which arers. Published by Elsevier Ltd.This is an open accestimated to cause over 14 million human
infections per annum.1 EHEC differ from EPEC by
the production of one or more Shiga toxins that
cause damage to vascular endothelia that can lead
to haemolytic uraemic syndrome. EPEC and EHEC
require a Type III secretion system (T3SS) for
intestinal colonisation that is encoded by the locusess article under the CC BY license (http://creativecommons.org/licenses/
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a set of effector proteins into enterocytes that sub-
vert cellular processes to the benefit of the patho-
gen, resulting in intimate adherence of the
bacteria to the apical surface of host cells on raised
actin-rich pedestals and effacement of microvilli.3
EPEC and EHEC express a number of additional
virulence factors that support infection,4 one of
which is the protein lymphostatin, which is encoded
proximal to the LEE in some strains. It is known to
be important for intestinal colonisation in cattle by
EHEC serogroup O5, O26 and O111 strains5,6
and for colonisation of mice by the murine attaching
& effacing pathogen Citrobacter rodentium.7
Although the precise mode of action of lymphostatin
remains ill-defined, it has been reported to act as an
inhibitor of the activation of T lymphocytes from a
number of species and tissues.5,8–12 Our laboratory
has found that lymphostatin is active against both
CD4 and CD8 subsets, exhibits modest activity
against B-cells but has very little effect on NK cells,
and inhibits the mitogen-activated synthesis of a
range of bovine proinflammatory cytokines.11 Lym-
phostatin has also been shown to influence adher-
ence in some strains,13 possibly as a
consequence of effects on Type III secretion.5,6 Fur-
ther, although LifA has been reported to be secreted
via the LEE-encoded T3SS14 and is involved in ped-
estal formation in EPEC strains that lack multiple
effectors,13 its activity against lymphocytes does
not require injection and can be observed following
treatment with highly purified protein.12
Lymphostatin is one of the largest E. coli proteins
known at 366 kDa (Figure 1) and is a putativeFigure 1. Lymphostatin is processed in bovine T lymphocy
with a molecular weight of approximately 140 kDa in the lys
absolute number of 1.2  107 cells were treated with/withou
was run in each well. Full-length WT rLifA (~366 kDa) and th
Predicted cleavage sites (in bold, highlighted cyan) of lymp
that lie between the first amino acid after the end of the predic
Underlined amino acids represent cleavage sites that would
of the observed putative cleavage product. (c) A schematic re
GT: glycosyltransferase domain, CYS:cysteine protease d
highlights the region of putative cleavage.
2
glycosyltransferase with homology over the N-
terminal third to large clostridial toxins (LCTs).10–13
The LCTs TcdA and TcdB are known to glucosylate
Rho-family GTPases that regulate the actin
cytoskeleton, ultimately inducing morphological
changes and cytotoxicity.16 LCTs from Clostridium
novyi (TcnA) and C. perfringens (TpeL) have been
reported to transfer N-acetylglucosamine (GlcNAc)
to Rho family and Ras GTPases from a uridine
diphosphate (UDP) sugar donor.17,18 Previously,
we have shown that recombinant lymphostatin is
able to bind uridine diphosphate N-
acetylglucosamine (UDP-GlcNAc),12 and that a
DTD motif in the N-terminal glycosyltransferase
domain is essential for both binding of the sugar
donor and inhibition of mitogen-activated T cell
proliferation.12
In addition to possession of a glycosyltransferase
domain, lymphostatin also shares a putative
cysteine protease motif with LCTs.13,19 This motif
is characterised by the presence of a catalytic triad
of Cys-His-Asp that is widely conserved in the C58
family of bacterial virulence factors that contain a
YopT-like domain19,20 (C1480, H1581, D1596 in
the prototype LifA protein from EPEC strain
E2348/69). In LCTs, the cysteine protease motif is
required to facilitate intracellular autocatalytic cleav-
age of the protein to release the glycosyltransferase
domain.21 Briefly, LCTs bind at the surface of the
target cell and undergo receptor-mediated endocy-
tosis. As the endosome matures, the internal pH of
the endosome drops, leading to structural changes
that promote insertion of the protein across the
endosomal membrane. The cysteine proteasemotiftes. (a) Western blots reveal a putative cleavage product
ates of bovine T lymphocytes treated with WT rLifA. An
t WT rLifA for 1 h. A volume equivalent to 2  106 cells
e putative cleavage product are indicated by arrows. (b)
hostatin, based on large clostridial toxin cleavage sites,
ted glycosyltransferase domain and the catalytic C1480.
produce an N-terminal product of approximately the size
presentation of the domain organisation of lymphostatin.
omain, DUF:domain of unknown function. A blue line
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using inositol hexakisphosphate as a co-factor,
allowing the release of the glycosyltransferase
domain into the cytosol.22 Some bacterial virulence
factors, such as YopT, use their cysteine protease
motif to cleave cellular targets, thereby producing
cytotoxic effects.19 However, published studies to
date have not identified direct cytotoxicity associ-
ated with LifA treatment (e.g. release of lactate
dehydrogenase or altered cellular morphology or
viability),10,12 suggesting that lymphostatin func-
tions in a different manner.
LifAcanbeencodedwithin thesamepathogenicity
island as Type III secreted effectors with
glycosyltransferase (NleB) and cysteine protease
(EspL) activities in the prototype EPEC strain
E2348/69.23 However, sequencing of non-O157
STEC strains has reported that the location of the
gene and composition of the pathogenicity island
encoding NleB and EspL can differ.24 EspL uses its
cysteine protease activity to cleave RHIM-
containing proteins (RIPK1, RIPK3, TRIF and
ZBP1/DAI) to prevent lipopolysaccharide or polyI:
C-induced inflammatory signalling.25 The presence
of an additional cysteine protease motif in lympho-
statin with potentially different specificity is
intriguing.
The cysteine protease motif of lymphostatin has
previously been reported to be required for colonic
colonisation of mice by C. rodentium and the
induction of hyperplasia.7 However, the method
used to generate a cysteine protease motif mutant
in this study resulted in the introduction of a stop
codon, causing protein truncation rather than an
in-frame deletion.6,26 A second study by the same
authors created an in-frame deletion of the C.
rodentium LifA cysteine protease motif, but the
effect on gut colonisation in mice and lymphostatin
activity was not reported.26 Separately, it was
reported that a chromosomal deletion of the cys-
teine protease motif in EPEC E2348/69 lifA
impaired the ability of cell lysates to inhibit the con-
canavalin A (ConA)-simulated proliferation of lym-
phocytes.6 The deletion encompassed a 369 bp
region that included residues C1480, H1581 and
D1596 and the impact of a significant change of this
nature on the structure of the protein was not
studied.
With the exception of these studies, little has been
done to investigate the role that the cysteine
protease motif plays in the activity or processing
of lymphostatin. We hypothesised that a cleavage
event, similar to that observed with LCTs, is
required for the full activity of lymphostatin on T
cells. We investigated this by analysing the
processing of LifA in T cells, structural modelling,
site-directed mutagenesis of the predicted
catalytic cysteine residue, purification and
biophysical analysis of the altered protein, and
analysis of the processing and activity of the
altered protein in T cells.3
Results
A processed form of lymphostatin appears in
bovine T cells
In order to investigate the hypothesis that
lymphostatin is processed in T cells, we analysed
lysates of T cells that had been treated with
recombinant LifA (rLifA) from EPEC E2348/69 by
western blotting using a polyclonal antibody that is
known to recognise multiple domains of the
protein (see Footnotes). If the cysteine protease
domain (CPD) of lymphostatin mediates
autocatalytic cleavage in a manner similar to the
LCTs, then we predicted that this cleavage should
yield a fragment of at least 100 kDa
encompassing the N-terminal glycosyltransferase
domain that we previously localised to residues
309–860,12 and another fragment of at least
265 kDa encompassing the rest of the molecule.
In T cells treated with wild-type rLifA (WT rLifA)
we observed a single specific and reproducible spe-
cies reactive to anti-LifA antibodies running at
approximately 140 kDa in SDS-PAGE (Figure 1(A)
and (C)), suggesting that lymphostatin is processed
in T cells. The 140 kDa species and the expected C-
terminal His-tagged species of 225 kDa were not
detected with anti-6  His antibodies, possibly
owing to the limit of sensitivity of the assay, reten-
tion in endosomes and degradation or masking by
a T cell protein reactive to anti-LifA antibodies.
Full-length intact rLifA (366 kDa) and non-specific
T cell species (at approximately 270, 230, 65 kDa
and below) were also detected. LCTs autocatalyti-
cally cleave between conserved leucine residues
and either serine, glycine or asparagine residues
located between the glycosyltransferase and cys-
teine protease motifs.27–29 Thirteen such potential
cleavage sites exist at the following residues in
strain E2348/69 lymphostatin: 1087, 1176, 1184,
1228, 1241, 1244, 1257, 1264, 1314, 1341, 1370,
1373 and 1440 (Figure 1(B)).Modelling the putative cysteine protease
domain of lymphostatin
To further investigate the proteolytic activity of
lymphostatin we sought to better define the
putative CPD. We assembled lymphostatin-like
CPD sequences with PSI-BLAST30 and aligned
them with Psi-Coffee (T-COFFEE, Version_11.00.
d625267 (2016–01-11 15:25:41 - Revision
d625267 - Build 507)).31 Phylogenetic analyses on
the aligned sequences were used to generate an
unrooted tree to guide our subsequent mod-
elling32–36 (Figure 2). Lymphostatin and LifA-like
proteins form a well-defined clade (blue). PaTox
and the “makes caterpillars floppy” toxins Mcf1
and Mcf2 are grouped together (green).37 The
majority of the YopT-like C58A subfamily, which
includes YopT from Yersinia pestis form a clade
Figure 2. Lymphostatin shares sequence conservation with C58 cysteine protease domains (CPDs). Partial
sequence alignments of MEROPS class C58 CPDs, lymphostatin (blue and bold) and lymphostatin-like CPDs were
assembled with PSI-BLAST and aligned with Psi-Coffee. Phylogenetic analysis of the aligned sequences was used to
generate an unrooted tree. Results from 100 bootstrap events have been used to annotate the branches of the tree
(> 50% support value). Atomic resolution structural information is available for AvrPphB from Pseudomonas syringae
(PDB ID: 1UKF) and PaTox from Photorhabdus asymbiotica (PDB ID: 6HV6); shown in bold. LifA shares higher
sequence identity with PaTox than AvrPphB. Sequence alignments, sequence accession numbers and annotation of
each catalytic triad are available in Supporting Information.
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bacterial plant pathogens (representative member
AvrPphB from Pseudomonas syringae). We
included the E.coli protein EspL and its close homo-
logue OspD3 from Shigella flexneri in our sequence
alignments as they are proteins with proven cys-
teine protease activity found in the same
pathogenicity island with other Type III secreted
effectors. Sequence alignments and detailed align-
ment procedures are provided in the Supporting
Information (Table S1 and Figures S1 and S2). Of
the available atomic resolution structures, PaTox
was the closest homologue and was used to build
a 3D model with the Phyre2 server.38 The probabil-
ity of the putative lymphostatin CPD (W1442–
Q1619) being homologous to the PaTox C58-like
CPD was 99.8%. Figure 3 shows the model of the
putative lymphostatin CPD (W1442–Q1619) anno-
tated to show the catalytic triad (C1480, H15814
and D1596) and Q1470. Q1470 is very well con-
served in C58 CPDs and is positioned in space to
facilitate the formation of the canonical oxyanion
hole necessary for the stabilisation of a negative
charge on a reaction intermediate. The active site
is annotated on the electrostatic surface shown in
Figure 3(B). The most likely binding interface was
further defined using the docking program
ArDock.39 It is interesting to note that most, but
not all the surface residues predicted to have a high
interaction propensity are very well conserved in
LifA-like proteins (Figures S2 and S3(A)). This is
best illustrated by the loop connecting a-helix-1 to
a-helix-2 (V1474–Q1476) that lies immediately
upstream of the catalytic cysteine motif: 1477[E,D]
G[R,K]C[M,I,L,V,T]G1482. The position of the vari-
able sequence close to the catalytic cysteine motif
where it flanks the oxyanion hole would suggest that
this sequence is key to substrate recognition. These
Figure 3. Lymphostatin has a C58 cysteine protease domain (CPD) with a putative papain-like fold. (a) A homology
model of the C58 CPD of LifA based on PaTox (PDB ID: 6HV6) constructed using the Phyre2 server.30 The protein
surface has been coloured according to surface residue interaction propensity calculated using the docking program
ArDock.31 The green surface represents the predicted enzyme active site. (b) Electrostatic surface representation of
the lymphostatin CPD. The putative binding site forms a neutral groove (white) with a neighbouring negatively
charged patch (red). (c) The CPD is displayed as a cartoon representation to highlight the papain-like fold predicted
from sequence. The catalytic triad (C1480, H1581, D1596) and Q1470 are shown as yellow sticks. Q1470 is predicted
to be placed to facilitate the formation of the canonical oxyanion hole necessary for the stabilisation of a negative
charge on a reaction intermediate in cysteine proteases. The chain direction is indicated with N and C. All images
have the same 3D orientation. Figures were prepared in PyMol (The PyMOL Molecular Graphics System, Version
2.4.0 Schrödinger, LLC).
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papain-like CPD.
Inhibitors of endosome acidification reduce
formation of the predicted cleavage product in
a concentration-dependent manner
Given that autocatalytic cleavage of the LCTs is
dependent on acidification of the endosome,
which induces a conformational change in the
protein leading to insertion across the endosomal
membrane, we investigated whether the
processing of lymphostatin may be sensitive to
bafilomycin A1 or chloroquine, which are known to
block endosome acidification across diverse cell
types and species. Bafilomycin A1 is a proton
pump inhibitor,40 while chloroquine is a lysoso-
motropic agent that inhibits endosomal acidification
through the prevention of lysosomal fusion.41 Sepa-
rate treatment of bovine T cells with increasing con-
centrations of both inhibitors reduced the
appearance of the 140 kDa species reactive to
anti-LifA antibodies (Figure 4). Densitometry of the
fluorescence intensity at this position (normalised
to b-actin signals then expressed as fold-change
relative to the diluent control over five independent
replicates of the study) revealed that at increased
concentrations of bafilomycin A1 and chloroquine,
significantly lower quantities of the 140 kDa frag-
ment are produced in comparison to the negative
controls, even accounting for the loss of b-actin sig-
nal at higher concentrations that may be a conse-
quence of cytotoxicity (Figure 4). Linear
regression slopes across five donors for both bafilo-5
mycin A1 and chloroquine-treated cells were signif-
icantly different from the null hypothesis that
inhibitor concentration has no effect on the pres-
ence of the 140 kDa cleavage product
(P < 0.001). Endosome acidification was therefore
inferred to be a requirement for the processing
event.
Mutation of C1480 of lymphostatin does not
affect biophysical properties of the protein
We know from previous studies that mutation of
any of the three residues of the CHD catalytic
triad abolishes activity of the CPD in LCTs and
C58 proteases.19,42,43 Here, we elected to mutate
C1480 in rLifA to a neutral alanine residue using
site-directed mutagenesis. During purification, the
resulting protein had similar purity, surface charge
properties and hydrodynamic radius to WT rLifA
and a DTD-AAA variant that we have also investi-
gated12 (Figure S4(A)–(C)). To verify that the muta-
tion did not grossly affect the folding and structure of
the purified protein, we examined biophysical prop-
erties of the rLifAC1480A protein and compared these
to WT rLifA. We detected rLifAC1480A at the same
position as WT rLifA by gel electrophoresis and
western blotting with anti-LifA antibodies
(Figure S4(D)). The identity of full-length
rLifAC1480A was confirmed by in-gel protein digest
and peptide mass fingerprinting. The peptide mass
map generated was searched against the NCBInr
database using the MASCOT search engine. Lym-
phostatin was identified as the top scoring hit with
a MASCOT protein score of 485. Peptides aligned
Figure 4. Inhibitors of endosomal acidification prevent lymphostatin cleavage. An absolute number of 1.2  107
bovine T cells were incubated with the indicated final concentrations of bafilomycin A1 or chloroquine for 1 h then
treated with WT rLifA for 1 h. A volume equivalent to 2  106 cells was run in each well. (a) Western blot of
bafilomycin-treated T cells shows that the appearance of the cleavage product (red box) is reduced with increasing
inhibitor concentration; DMSO was used as the 0 mM control. (b) Western blot of chloroquine-treated T cells shows
that presence of cleavage product remains constant between 0.0125 and 12.5 lM but is reduced at higher
concentrations; PBS was used as the 0 mM control. Data were generated from 5 independent donors and a
representative blot is shown. Quantification of signal by densitometry was performed on the western blots. The
quantity of cleavage product at each inhibitor concentration was normalised against its respective actin signal to
account for protein loading across the gel. Data were normalised again against the appropriate 0 mM controls to give a
fold change in normalised signal compared to untreated cells. (c) Average fold change in normalised signal of
bafilomycin-treated T cells with titration of inhibitor concentration. (d) Average fold change in normalised signal of
chloroquine-treated T cells with titration of inhibitor concentration. Error bars indicate standard deviation of the
average fold changes from 5 experiments.
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Glu60 to Arg3174 (of 3229), consistent with earlier
analyses of theWT protein.12 rLifAC1480A was found
to be of a similar hydrodynamic radius to the mono-
meric WT protein by dynamic light scattering and
eluted at the same position asWT rLifA in analytical
size-exclusion chromatography (Figure 5(A) and
(B)). rLifAC1480A eluted as a single peak with an elu-
tion volume of 1.46 ± 0.01 mL, whereas monomeric
rLifA protein eluted at 1.47 ± 0.01 mL (Superose 6
Increase 3.2/300, GE Healthcare). Analysis of sec-
ondary structure of WT rLifA and rLifAC1480A by cir-
cular dichroism spectroscopy revealed a near-
identical spectrum, showing similar a-helical con-
tent (approximately 44% WT rLifA and 46%6
rLifAC1480A), as well as b-strand content (approxi-
mately 16%WT rLifA and 13% rLifAC1480A, Figure 5
(C) and (E)). Subtle changes to the secondary or
tertiary structure of a protein can influence the
Gibbs free energy of unfolding and its associated
mid-point melting transition (Tm).
44,45 We therefore
used thermal denaturation fluorescence assays to
measure the stability of the protein structure, which
yielded a Tm of 41 C and almost indistinguishable
melting curves (Figure 5(D) and (F)). Taken
together, these assays indicate that the mutant pro-
tein is near-identical in secondary and tertiary struc-
ture to WT lymphostatin.
To compare the three-dimensional structure of
rLifAC1480A to WT rLifA, we undertook a SAXS
Figure 5. Biophysical analysis of rLifAC1480A. (a) rLifAC1480A has the same hydrodynamic radius as WT rLifA; there
was no evidence of aggregated protein in either sample. The size distribution by intensity of 1.1 mM rLifAC1480A (Rh
78 ± 26A; mode and SD of the intensity distribution) compared to 1.1 mMWT rLifA (Rh 78 ± 29A; mode and SD of the
intensity distribution), measured by dynamic light scattering. (b) Analytical size-exclusion chromatography of
rLifAC1480A and WT rLifA (Superose 6 Increase 3.2/300). (c) The CD spectra of 0.11 mM WT rLifA and rLifAC1480A. Far
UV CD spectra expressed in mean residue ellipticity (MRE) as a function of wavelength. (d) WT rLifA and rLifAC1480A
thermal stability. The fluorescence of SYPRO Orange dye mixed with 0.1 lM WT rLifA and rLifAC1480A was measured
in triplicate over a temperature range of 15–70 C to determine the Tm of each protein. A reproducible Tm of ~41 C
was observed for both proteins. (e) Secondary structural elements derived from the CD spectra of WT rLifA and
rLifAC1480A. (f) Tm for WT rLifA and rLifA
C1480A.
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chromatography. Transformation of the scattering
data gave a linear Guinier region indicative of an
absence of interparticle effects; Rg 58.9 ± 1.7 A
(Figure 6(A)). The real space pair distribution
function reflects the scattering from a slightly
elongated globular particle (Figure 6(B)). The
longest particle dimension Dmax is 191 A. The real
space Rg 59.8 ± 0.0 A calculated from the P(r)
function is consistent with the result from Guinier
analysis which strengthens the validity of the
solution. Kratky analysis shows an almost bell-7
shaped curve that converges to the q axis with
increasing q (Figure 6(C)). The peak maxima for
rLifAC1480A is close to the Kratky-Guinier point, the
peak position for an ideal globular protein. The
Porod volume (Vp) was determined to be
557285 A3. These data are essentially identical to
SEC-SAXS data collected for WT rLifA; Dmax is
193 A, Rg(Guinier) 58.7 ± 1.2 A, Rg(real) 59.4 ± 2.0 A
Vp 559196 A
3 purified under the same conditions
as rLifAC1480A as part of this study (Figure 6(D)).
We undertook ab initio shape determination to
compare the particle envelope of rLifAC1480A to
Figure 6. SAXS analysis of rLifAC1480A. (a) The experimental SAXS scattering curve of rLifAC1480A. The logarithm of
the SAXS intensity versus the scattering vector, q (A1). The linear region of the Guinier plot (ln[I(q)] versus q2) is
shown as an inset. (b) The Pair-distance distribution function of rLifAC1480A. (c) The dimensionless Kratky plot (I(q)/I(0)
*(q*Rg)
2) of rLifAC1480A is consistent with that of a globular protein. (d) A comparison of the scattering curves of WT
rLifA and rLifAC1480A normalised to I(0). (e) WT rLifA and rLifAC1480A have very similar geometric parameters. (f)
Negative stain electron microscopy envelope of WT rLifA (blue) reported in our previous publication.10 Electron
density map generated from solution scattering using DENSS for rLifAC1480A and WT rLifA shown in two views related
by a 90 rotation around the horizontal axis. Maps are shown as volumes and coloured according to density;
red > orange > yellow > green > blue.
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protein that has proved recalcitrant to
crystallographic study. Kratky analysis of 1D
scattering profiles (Figure 6(C)) and preliminary8
cryo-electron diffraction experiments suggest that
there is some flexibility within this large molecule
in solution. Traditional bead modelling algorithms
generate models with no indication of electron
A.G. Bease, E.A. Blackburn, C. Chintoan-Uta, et al. Journal of Molecular Biology 433 (2021) 167200density within the particle envelope. Moreover, for
flexible molecules generating a large number of
bead models, averaging them and filtering to
retain a specific bead of high probability invariably
produces an envelope with an artefactually small
molecular envelope that excludes extended
flexible regions. To better investigate variations in
electron density within lymphostatin we calculated
3D electron density maps from the solution
scattering data using the program DENSS
(DENsity from Solution Scattering) which employs
iterative phase and structure factor retrieval.46
A comparison of the predicted shape and
dimensions of rLifAC1480A and rLifA obtained by
SAXS and EM (Figure 6(F)) support the notion
that rLifAC1480A has a very similar architecture to
the WT protein.12 We cannot preclude the possibil-
ity that the C1480A substitution causes small con-
formational changes that would not be detected at
this resolution. To further validate our electron den-
sity maps, we fitted our homology models of the gly-
cosyltransferase domain and CPD of lymphostatin
to the maps, basing the domain orientation on the
crystal structure of the homologous TcdA from
Clostridium difficile (PDB ID: 4R04, Figure S5).
The domain arrangement both fits well in terms of
putative electron density and exposes the active
sites of the glycosyltransferase and cysteine pro-
tease domains to solvent where there is an access
route for a substrate. We hypothesise that the lar-
gest lobe of our ab initio shape determination envel-
ope represents the glycosyltransferase domain.
This is consistent with SAXS data we have obtained
for fragments of lymphostatin (data not shown).
LCTs undergo a conformational change and
autocatalytic cleavage upon on acidification of the
endosome. To investigate the effect of pH upon
the conformation of lymphostatin we repeated the
SEC-SAXS analysis at pH 5.5. We have
consistently observed that WT rLifA and
rLifAC1480A elute later in size-exclusion
chromatography under acidic conditions
(Table S2). This represents a change in stokes
radius/hydrodynamic character. Analysis of the
scattering data confirmed both rLifA and
rLifAC1480A remain monomeric in solution at pH 5.5
and that there was no evidence of protein
aggregation. Rg and Dmax at pH 5.5 and pH 7.5
are indistinguishable for both rLifA and rLifAC1480A.
The Porod volume was slightly larger and the
Porod exponent smaller at pH 5.5 compared to pH
7.5 for both WT and mutant proteins. A smaller
Porod exponent is indicative of a more flexible
system. The electron density maps generated for
WT rLifA and rLifAC1480A at pH 5.5 occupy similar
volumes, but there does appear to be slightly less
well defined centres of electron density
(Figure S6). We conclude that the change from
neutral to acidic pH does not induce any gross
structural changes, but results in a small increase
in flexibility under acidic conditions.9
Mutation of C1480 of lymphostatin abolishes
the appearance of the 140 kDa sub-fragment
In T cells treated with the WT rLifA protein, the
approximately 140 kDa species reactive with anti-
LifA antibodies was clearly evident by 15 min after
addition of the protein, and the signal intensity
increased up to 1 h post-addition (Figure 7). In
contrast, the 140 kDa protein was not observed in
the lysates of T cells treated with rLifAC1480A at
any time post-addition (Figure 7). As phenotypes
attributable to LifA have been described in other
cell types, including inhibition of mitogen-activated
IL-2 synthesis in Jurkat cells9 and pedestal forma-
tion on epithelial cells,15 we examined if processing
of LifA could be detected in J774A.1 murine
macrophage-like cells. In J774A.1 cells treated with
WT rLifA protein, both the approximately 140 kDa
and the approximately 225 kDa species reactive
to anti-LifA antibodies could be detected after 1 h
(Figure S7(A)). In contrast, these proteins were
not observed in the lysates of J774A.1 cells treated
with rLifAC1480A (Figure S7). Additionally, the
225 kDa species was reactive to anti-6  His anti-
body, indicating that it is the C-terminal portion of
lymphostatin (Figure S7(B)).
The C1480A substitution abolishes
lymphostatin activity
Purified lymphostatin is a potent inhibitor of the
mitogen- and antigen-stimulated proliferation of
bovine T cells, including all key subsets.11,12 We
therefore investigated whether the C1480A substi-
tution affected this activity. Using T cells from five
independent donors, rLifAC1480A was shown to have
a markedly reduced ability to inhibit ConA-
stimulated T cell proliferation in comparison to WT
rLifA (Figure 8). The 50% effective dose (ED50) of
rLifAC1480A was 5 orders of magnitude higher than
that of WT rLifA (ED50 WT rLifA = 0.014 ± 0.004 n
g/mL, ED50 rLifA
C1480A = 1215 ± 684 ng/mL). This
increase in ED50 was highly significant across five
donors (P = 0.0097) and was comparable to that
seen previously for lymphostatin with a substitution
of three alanine residues for a DTD motif in the gly-
cosyltransferase domain (rLifADTD-AAA).12 Our data
indicate that the cysteine protease motif is required
for the ability of lymphostatin to block mitogen-
activated proliferation of bovine T cells, without
obvious alteration of its secondary or tertiary
structure.
Concentration-dependent inhibition of
concanavalin A-activated proliferation of
bovine T cells by wild-type lymphostatin is not
associated with direct cytotoxicity
To confirm that lymphostatin is not associated
with direct cytotoxicity we measured the release
of lactate dehydrogenase (LDH). Three replicates
of the proliferation assays were set up in
Figure 7. Cleavage of lymphostatin in T cells is dependent on the cysteine protease motif. Western blot of lysates
from T cells (1.2  107 cells) treated with rLifA and rLifAC1480A for varying durations. An approximately 140 kDa
cleavage product of rLifA is barely visible at 5 min post-incubation and increases in concentration up to 1 h after
treatment (marked with black arrow), while no cleavage product is observed in LifAC1480A treated T cells even after 2 h
(red arrow indicates where cleavage product would be expected to be observed). Quantities of 2 ng of rLifA or
rLifAC1480A were used as positive (+ve) controls. Data were generated from 2 independent donors and a blot is shown
from a representative donor.
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ability of LifA to inhibit cellular proliferation and
two to be used for measurement of LifA’s
cytotoxicity at time intervals of 24 and 72 h post-
treatment (Figure S8). At 24 h post-treatment,
percent cytotoxicity was largely unchanged
across the LifA concentration range, indicating
that the effect on lymphocyte proliferation is not
associated with direct cytotoxicity (Figure S8(B)).
At 72 h post-treatment, at concentrations of LifA
insufficient to block proliferation, the lymphocytes
are driven to exhaustion by the mitogen resulting
in significant LDH release (Figure S8(C)).
However, at concentrations where LifA achieves
saturating inhibition of lymphocyte proliferation
( 0.1 mg/mL and above), negligible LDH release
was observed.10Discussion
Elucidation of the molecular mechanisms
underlying microbial pathogenesis can inform the
design of strategies to control infections and yield
insights into host cell biology. Here we
characterised the putative cysteine protease motif
of lymphostatin, a virulence factor produced by
attaching & effacing E. coli. Although we know
from previous studies that the activity of
lymphostatin is dependent on the presence of a
glycosyltransferase motif,12 there has been little
investigation of the role of other recognised motifs
within lymphostatin, including the cysteine protease
domain which mediates autocatalytic processing of
the structurally homologous large clostridial
toxins.42,43
Figure 8. The C1480A substitution abolishes inhibi-
tory activity of lymphostatin. Effect of concentration
titration of WT rLifA and rLifAC1480A against ConA-
stimulated peripheral bovine T lymphocytes. An abso-
lute number of 200,000 cells were seeded into the wells
of a 96 well plate. Titrations were carried out in triplicate
per donor and the results are the average obtained from
5 independent experiments using separate donors. Data
were normalised against cells with ConA alone to give a
ratio index of proliferation. Error bars indicate the
standard deviation of the average ratios from across
the 5 experiments. The calculated ED50 was
0.014 ± 0.004 ng/mL (WT rLifA) and 1215 ± 684 ng/
mL (rLifAC1480). ED50 Values for each donor can be
found in Table S3.
A.G. Bease, E.A. Blackburn, C. Chintoan-Uta, et al. Journal of Molecular Biology 433 (2021) 167200By western blotting of lymphostatin-treated
bovine T cells, we observed the appearance of a
single specific anti-LifA-reactive species of
approximately 140 kDa, consistent with
expectations for the glycosyltransferase domain of
LifA and autocatalytic cleavage at a site N-
terminal to the cysteine protease motif, as
described for LCTs.27–29 We were unable to
observe the predicted 225 kDa species represent-
ing the predicted C-terminal portion of lymphostatin
in T cells, however, this was detected in J774A.1
cells treated with rLifA. It is possible that this
reflects differences in the rate of uptake and pro-
cessing of rLifA, variation in the rate of retention
and degradation of the 225 kDa fragment in endo-
somes, and/or the limit of detection of the assay
used. Additionally, since we observed non-specific
reactivity of the antibody with T cell proteins at
around the same size, this may have obscured
the 225 kDa species. As autocatalytic cleavage of
LCTs by the cysteine protease motif requires inos-
itol hexakisphosphate as a co-factor,21,27–29 we
attempted to detect processing of WT rLifA in the
presence of this molecule in vitro. However, we
were unable to observe specific processing of the11protein, albeit further optimisation of the assay con-
ditions may be required.12
We also attempted to determine whether
lymphostatin is capable of acting as a protease
against host proteins similar to other C58
proteases.19,47 Even if the cysteine protease motif
is responsible for autocatalytic cleavage, it may also
cleave host proteins, as observed for AvrPphB, a
C58 protease produced by P. syringae. In AvrPphB
the cysteine protease motif is required for autocat-
alytic cleavage of the protein to expose a myristoy-
lation site and also the cleavage of the host cell
protein kinase PBS1.19,47,48 In an assay using
release of fluorescein-conjugated peptides from
labelled casein as a model host substrate cleaved
by a variety of proteases, we were unable to detect
protease activity of WT rLifA in vitro, at least under
the conditions tested (see Footnotes).
The appearance of 140 and 225 kDa proteins
detectable by anti-LifA antibody in a manner
dependent on residue C1480 is consistent with
autocatalytic cleavage by a mechanism similar to
LCTs. As a result, it would be desirable to confirm
the location of the cleavage site that produces
these two fragments. We were unable to detect
LifA-derived tryptic peptides from gel slices of
electrophoresed lysates of T cells treated with WT
rLifA at 140 kDa by mass spectrometry, likely as
the species is present at very low abundance in
an excess of lymphocyte proteins. Confirmation of
the cleavage site would likely require
immunoprecipitation of the fragments from a large
quantity of rLifA-treated T or J774A.1 cells. We
anticipate that the 140 kDa fragment
encompasses the N-terminal glycosyltransferase
domain required for lymphostatin activity. In line
with this, we further hypothesise that this fragment
acts on an intracellular target after processing and
that the C-terminal fragment is responsible for
binding and uptake of lymphostatin. We sought to
test the activity of the N-terminal fragment by
direct delivery of a rLifA fragment encompassing
residues 1–1620 including the glycosyltransferase
domain (informed by limited proteolysis of rLifA)12
to the cytoplasm. Unfortunately, these studies were
impeded by the fact that the protein transfection
reagent used was able to activate primary T cells
(see Footnotes).
The appearance of the 140 kDa fragment of rLifA
was shown to be dependent on endosomal
acidification using a proton pump inhibitor
(bafilomycin A1) and a lysosomotropic agent
(chloroquine). Treating cells with increasing
amounts of the inhibitors poisons the cells, such
that it is not possible to titrate the appearance of
the fragment to, or close to, zero. Better
understanding the effect of pH on processing of
lymphostatin would be more controlled in an
in vitro biochemical assay, however, this is
dependent on identifying any co-factor that is
required, which so far has been elusive.
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in the flexibility of rLifA and rLifAC1480A and a
concomitant change in the volume of the
molecular envelope in acidic buffers. Increasing
protein flexibility means that in acidic conditions
lymphostatin samples new conformations. This
change in flexibility is not sufficient to activate
autocatalytic cleavage in vitro but may well
expose a co-factor binding site or remodel part of
the protein to facilitate membrane insertion in host
cells.
The C1480A substitution herein represents a less
intrusive change to the lymphostatin protein than
has previously been reported using in-frame
deletions that encompass the CHD catalytic triad
(residues 1478–16006 or residues 1453–1480.7,26
The impact of these deletion mutations has been
reported, for example a loss of lymphostatin activ-
ity6 and impacts on E-cadherin and b-catenin at api-
cal enterocyte junctions.26 However, in these
studies it was unclear if indirect effects of the muta-
tions on secondary or tertiary structure of the pro-
tein may have occurred. Our biophysical
measurements suggest minimal impact of the
C1480A substitution, and consequently we infer
that the observed impact of lymphostatin activity
reflects the role of the cysteine protease domain
per se.Materials and Methods
Site-directed mutagenesis of LifA
The cysteine residue at amino acid position 1480
of full-length lymphostatin from the prototype EPEC
O127:H6 strain E2348/69 was mutated to an
alanine residue by site-directed mutagenesis
(QuikChange II XL, Agilent Technologies)
according to the manufacturer’s instructions. Our
previously described construct for rhamnose-
inducible expression of a histidine-tagged version
of LifA was used as a template (pRHAM-LifA-





AG30, were used to introduce the mutation. For
ease of screening, a BsrDI restriction site (under-
lined) was introduced to the sequence at the site
of the C1480A substitution (indicated in bold).
Putative plasmid clones were screened for the
substitution by BsrDI digestion of amplicons span-
ning the target sequence and candidate mutants
were analysed by Sanger sequencing of both
strands (GATC Biotech and Edinburgh Geno-
mics). A clone with 100% nucleotide identity to
the native lifA sequence over the full length of the
gene, except at the site of C1480A substitution,
was selected.12Expression and purification of recombinant
LifAC1480A
Recombinant His-tagged lymphostatin
harbouring the C1480A substitution (rLifAC1480A)
was overexpressed and purified using the same
method previously described for WT rLifA and a
DTD-AAA variant (Figure S4).12 WT rLifA was puri-
fied using an existing expression clone12 by the
same method with near identical purification char-
acteristics. The presence of lymphostatin after
expression and at each purification step was moni-
tored by SDS-PAGE and either Coomassie staining
of 4–12% Tris-glycine gels or western blotting of 3–
8% Tris-acetate gels with a rabbit polyclonal anti-
LifA antibody, clone 45 (generated by Dundee Cell
Products using purified full-lengthWT rLifA protein).
Membranes were blocked with Odyssey Blocking
buffer in TBS (LI-COR Biosciences) for 1 h at room
temperature on a rocker. Membranes were washed
three times with TSB-T (TBS with 0.1% (v/v) Tween
20 (VWR International)) then anti-LifA pAb serum
was added to membranes at a dilution of 1/20,000
in TBS-T and incubated a 4 C overnight on a
rocker. Membranes were washed twice with TBS-
T, with a third wash using PBS-T (PBS with 0.1%
Tween 20). Bound antibody was detected using a
goat anti-rabbit IgG antibody conjugated to
DyLightTM 800 (green) 4X polyethylene glycol-
conjugated fluorescent dye (Cell Signaling Technol-
ogy) diluted 1/30,000 in PBS-T and incubated at
room temperature for 1 hour on a rocker. Blots were
washed three times with PBS-T then imaged using
a LI-COR Odyssey Imaging System (LI-COR
Biosciences).Analytical size-exclusion chromatography
Analytical size-exclusion chromatography was
performed on the purified WT rLifA and rLifAC1480A
for comparison. A volume of 25 mL of 0.11 mM
lymphostatin was loaded onto a Superose 6
Increase 3.2/300 size-exclusion chromatography
column (GE Healthcare) pre-equilibrated in 50 mM
Bis-Tris, pH 7.5, 100 mM NaCl, 3% (v/v) glycerol
at a flow rate of 0.05 mL/min on an ÄKTAmicro
chromatography system (GE Healthcare).Dynamic light scattering
WT rLifA and rLifAC1480A were exchanged into
Assay Buffer (10 mM Tris, pH 7.6, 150 mM NaCl)
using a HiTrap desalt column (GE Healthcare) at
a flow rate of 4 mL/min, and centrifuged at
12,000g, 4 C for 15 min to remove any dust
particles that might interfere with size estimation.
The mean hydrodynamic radius of a 1.1 mM
solution of lymphostatin was measured using a
Zetasizer Automated Plate Sampler (Malvern
Instruments, UK) equipped with a 50 mW laser
light source, with a wavelength of 830 nm. Data
were collected at a scattering angle of 90 at 25 
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average autocorrelation data was fitted to a model
optimised for protein solutions using the software
supplied with the instrument. This analysis
generated a distribution of particles by size.49
Experiments were repeated five times.Matrix assisted laser-desorption ionisation
(MALDI) mass spectrometry
Excised SDS-PAGE gel-bands of rLifAC1480A
were incubated in 50 mM ammonium bicarbonate
containing porcine trypsin (Promega) in a
trypsin:lymphostatin ratio of ~1:30, overnight at
32 C. Peptides were identified by MALDI mass
spectroscopy on an ultrafleXtremeTM mass
spectrometer (Bruker) using an a-cyano-4-
hydroxycinnamic acid matrix. A peptide mass map
was generated from spectral data using Compass
DataAnalysis 4.4 software (Bruker). Peptide
masses were searched against the National
Center for Biotechnology Information database of
non-identical protein sequences (NCBInr) with the
MASCOT search engine,50 mass tolerance of
10 ppm (Matrix Science). Peptide masses were
also compared to the sequence of full-length LifA
from EPEC E2348/69 (Protein Prospector soft-
ware).12,13,51 The instrument was calibrated prior
to each data acquisition and an internal calibration
performed on the digest products of porcine trypsin.Circular dichroism (CD)
The far ultraviolet (UV) CD spectra of 0.11 mMWT
rLifA and rLifAC1480A were recorded at 10 nm/min;
data pitch 0.1 nm; response time 2 s between 185
and 285 nm in a 0.1 cm path length quartz cuvette
at 25 C (Jasco-810 spectropolarimeter). The
proteins were exchanged into 10 mM NaH2PO4,
pH 7.6, 100 mM NaF prior to analysis using a
HiTrap desalt column (GE Healthcare) at a flow
rate of 4 mL/min. Spectra were corrected by
subtracting a buffer baseline, each an average of
five spectra, acquired under the same conditions.
Secondary structure was estimated using the
DichroWeb CD secondary structure analysis
server52 including the methods CONTIN, SEL-
CON3 and CDSSTR53–56 and reference data sets
3, 4, 6, 7, SP175 and SMP180.Thermal denaturation fluorescence assays
The temperature-induced unfolding of
lymphostatin was followed using the
environmentally sensitive dye SYPRO Orange
(Invitrogen). SYPRO Orange shows an increase
in fluorescence correlated with the exposure of
hydrophobic residues upon unfolding.44,45 The flu-
orescence of WT rLifA and rLifAC1480A (both
0.1 mM) in 5  SYPRO Orange was measured
between 15 and 70 C at 0.5 C increments every
30 s (Bio-Rad IQ5 Multicolor Real-Time PCR13Detection System). The proteins were exchanged
into Assay Buffer prior to analysis using a HiTrap
desalt column (GE Healthcare) at a flow rate of
4 mL/min. Relative fluorescence units (RFU) for
each sample were plotted against temperature
and the unfolding transition temperature (Tm) of
each protein was calculated from the steepest part
of the melting curve. Experiments were repeated
in triplicate.Small angle X-ray scattering coupled to size-
exclusion chromatography (SEC-SAXS)
Small angle X-ray scattering (SAXS)
measurements were carried out on beamline
B21 at Diamond Light Source, Didcot, UK;
Experiment No. SM18931-1; fixed camera
length configuration (4.014 meters; useful q
range 0.0031 to 0.38 A1); 12.4 keV beam. A
volume of 45 mL of 2 mg/mL rLifAC1480A was
loaded onto a Superose 6 Increase 3.2/300
size-exclusion chromatography column (GE
Healthcare) pre-equilibrated in 50 mM Bis-Tris,
pH 7.5, 100 mM NaCl, 3% (v/v) glycerol; 15 C
at a flow rate of 0.075 mL/min using an Agilent
1200 HPLC system. Small angle X-ray
scattering was collected on the sample as it
eluted from the column in 10 s acquisition
blocks at 15 C. SAXS data reduction was
performed in the Diamond Light Source
software pipeline; ScAtter (v3.1v).57 Analysis of
SEC-SAXS data segments was carried out in
ScAtter (http://www.bioisis.net/scatter). Simple
geometric parameters were calculated using
ScAtter, PRIMUS and the ATSAS 2.8.34 suite
of programs.58 DENSS was run 20 times in the
slow mode, each time with a different random
seed. The maps fitting the data (19 maps in
total), were aligned with automated enantiomer
generation and selection, averaged, and refined.
Electron density maps are shown as volumes
and coloured according to density;
red > orange > yellow > green > blue. Figures
were drawn in the molecular graphics program
USCF Chimera59 and PyMol (The PyMOL Molec-
ular Graphics System, Version 2.4.0 Schrödinger,
LLC).Isolation of peripheral blood mononuclear
cells and T lymphocytes from bovine blood
Animal use was approved by the local Animal
Welfare and Ethical Review Board and venous
blood was collected from 12 to 18-month-old
Holstein-Friesian cows (200 mL per donor per
sampling day) in full compliance with requirements
of the Animals (Scientific Procedures) Act 1986.
Peripheral blood mononuclear cells were isolated
and T lymphocytes subsequently enriched using
sterile wool columns (Park Scientific) as previously
described.12 T cell enrichment was monitored by
flow cytometry of cells stained with anti-CD3 anti-
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achieved was 74.3% (54.9–90%). All samples were
analysed with single channel staining on an LSR
Fortessa X20 using CellQuest (BD Biosciences)
and FlowJo v10 software (Tree Star). A minimum
of 10,000 events were collected with an initial gate
for live cells based on forward/side scatter
parameters.Analysis of lymphostatin processing in T cells
Enriched peripheral bovine T cells (1.2  107
cells) were incubated in serum-free Roswell Park
Memorial Institute (RPMI-1640) medium with
25 mM HEPES (Sigma). After 1 h, WT rLifA or
rLifAC1480A was added to the cells at a final
concentration of 2 mg/mL and incubated at 37 C
for the times indicated. Cells were washed twice
with ice-cold phosphate-buffered saline (PBS),
pelleting the cells in between by centrifugation at
17,949g, 4 C for 1 min. As free lymphostatin
sticks to plastic, the cells were transferred to clean
microcentrifuge tubes after each wash. Cells
(1.33  108 cells/mL) were lysed with 90 mL of
NP-40 lysis buffer (20 mM Tris, pH 7.4, 150 mM
NaCl, 2 mM EGTA, 50 mM NaF, 1% (v/v) NP-40,
1 mM EDTA, 1 mM sodium orthovanadate, 1
cOTMmplete mini protease inhibitor tablet/10 mL)
and incubated on ice for 30 min. Insoluble debris
was removed by centrifugation (17,949g, 4 C for
10 min). Supernatants were denatured at 70 C
with 1  NuPAGE sample reducing agent and
1  NuPAGE LDS sample buffer (Invitrogen) for
10 min and stored at 20 C until required.
Western blots were performed using rabbit
polyclonal anti-LifA as described above with 5%
bovine serum albumin (Merck) in TBS-T used as
an initial blocking agent. All washes were
performed with TBS-T. Bound antibody was
detected using a goat anti-rabbit IgG conjugated
to horseradish peroxidase (Bio-Rad) diluted
1/10,000 with 2% (w/v) skimmed milk powder
(Chem Cruz) as a blocking agent. HRP-
conjugated signals were captured using
SuperSignalTM (Thermo Scientific) and Hyperfilm
ECL autoradiography film (GE Healthcare Life
Sciences).Analysis of lymphostatin processing in
J774A.1 cells
J774A.1 murine macrophage-like cells (1  106
cells/well; ATCC) were seeded into 12 well flat
bottom plates (Costar) for 24 h then incubated in
serum-free RPMI-1640 medium with 25 mM
HEPES. After 1 h, WT rLifA or rLifAC1480A was
added to the cells at a final concentration of 1 mg/
mL and incubated at 37 C for 1 h. Cells
(8.33  106 cells/mL) were lysed with 120 mL of
NP-40 lysis buffer and processed as described
above. Western blots were performed using rabbit
polyclonal anti-LifA or mouse monoclonal anti-146  His (BioLegend) as described above. Bound
antibody was detected using a goat anti-rabbit IgG
antibody conjugated to DyLightTM 800 (green) 4X
polyethylene glycol-conjugated fluorescent dye or
anti-mouse IgG conjugated to DyLightTM 800
(green) fluorescent dye using a LI-COR Odyssey
Imaging System (LI-COR Biosciences).Inhibition of endosome acidification
To examine the effects of inhibitors of endosomal
acidification on lymphostatin cleavage, T cells were
incubated in serum-free RPMI medium
supplemented with 25 mM HEPES. The inhibitors
were added at a range of concentrations with
bafilomycin A1 (50–0.0005 mM, LC Laboratories)
or chloroquine diphosphate (1250–0.0125 mM,
Sigma) informed by previous studies.60,61 Dimethyl-
sulphoxide (DMSO) and PBS were used as carrier
controls, respectively. Fluorescent western blot
analysis was used to detect LifA or predicted cleav-
age products thereof, and b-actin was detected as
an internal standard using mouse anti-bovine actin
(GeneTex) detected with goat anti-mouse IgG con-
jugated to DyLightTM 680 (red) fluorescent dye (Cell
Signaling Technology). Blots were scanned using a
LI-COR Odyssey Imaging System (LI-COR Bio-
sciences), and densitometry was performed using
Image Studio Lite v5.2 (LI-COR Biosciences). Den-
sitometry was performed by first normalising the flu-
orescent signal of the lymphostatin cleavage
product at each inhibitor concentration to its respec-
tive b-actin control. Data were normalised again to
the appropriate carrier control to give fold changes
in normalised fluorescent signal.Lymphocyte proliferation assay
Enriched bovine T cells were used to test the
ability of WT rLifA and rLifAC1480A to inhibit the
mitogen-activated proliferation of lymphocytes as
previously described.12 Briefly, cells were plated at
2  105 cells/well in 96 well flat bottom plates
(Costar) in triplicate for all conditions. Proteins were
added at the concentrations as indicated. Cell prolif-
eration was stimulated using ConA (Sigma) at a
final concentration of 1 mg/mL in the presence or
absence ofWT rLifA or rLifAC1480A at the concentra-
tions indicated in a final volume of 100 mL/well. Cells
were incubated at 37 C for 72 h. The colorimetric
substrate CellTiter 96 AQueous One (Promega)
was added 18 h before the end of the assay. All
measurements were carried out at 492 nm on a
Multiskan Ascent plate reader (Thermo Scientific).
Cells and medium alone were used as negative
controls. Background medium measurements were
subtracted from all values. All treatments are
expressed as a Proliferation Index calculated as
the ratio of Absorbance (Cells treated with ConA
and recombinant protein)/Absorbance (Cells trea-
ted with ConA alone).
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Cytotoxicity assays were performed in parallel
with proliferation assays, using T cells purified as
described above, from the same batch from three
separate donors. Three replicates of the
proliferation assays were set up in parallel, one to
be used for measurement of the ability of LifA to
inhibit cellular proliferation and two to be used for
measurement of LifA’s cytotoxicity. At 24 and 72 h
post-incubation, cytotoxicity was measured via an
LDH release assay, using the Cytotoxicity
Detection KitPlus (LDH) (Roche, UK), following
manufacturer’s instructions. Cytotoxicity was
expressed as a percent cytotoxicity, calculated as
(Absorbance (cells treated with ConA and
recombinant LifA)  Absorbance (untreated
cells))/(Absorbance (positive control
cells)  Absorbance (untreated cells))  100.
Statistical analyses
Calculation of the effective dose of WT rLifA and
rLifAC1480A to inhibit T cell proliferation by 50%
(ED50) was determined using drc in R.32,62 The dif-
ferences between ED50 values for rLifA and
rLifAC1480A were calculated for each donor then
transformed by log10. A one sample T-test was
used to determine whether the difference in
ED50s, transformed by log10, were statistically sig-
nificantly different. Linear regression analysis was
carried out for the endosomal inhibitor experiments
usingMinitab 17.63 Average regression slopes were
tested for statistical significance using a one-
sample T-test. P values  0.05 were taken to be
statistically significant.
Accession numbers
Small angle scattering data and structural models
have been deposited at the Small Angle Scattering
Biological Data Bank (SASBDB) (https://www.
sasbdb.org/) with the following accession
numbers: SASDKL9 (WT rLifA pH7.5),
SASDKM9 (WT rLifA pH5.5), SASDKN9
(rLifAC1480A pH7.5), SASDKP9 (rLifAC1480A pH5.5).
Footnotes
Bease, A. G. (2019) Mode of action of a novel
lymphocyte inhibitory factor of attaching & effacing
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